GenMark Diagnostics has appointed Scott Mendel, its chief operating officer, as interim president and CEO, effective immediately. Hany Massarany has stepped down as president and CEO and as a member of the company’s board of directors, also effective immediately. GenMark said it has commenced a search to identify a permanent CEO.
The Carlsbad, Calif.-based firm said that its board of directors has appointed Hany Massarany as its new president and CEO. Massarany has served as president of Ventana Medical Systems and Head of Roche Tissue Diagnostics since February 2009. He spent 10 years at Ventana in various executive positions, including COO and EVP of worldwide operations. Ventana was acquired by Roche in February 2008 for around $3.4 billion.
Illumina has appointed Scott Gottlieb to its board of directors. Gottlieb is currently a special partner at New Enterprises Associates and a resident fellow at the American Enterprise Institute. He previously served as the 23rd commissioner of the US Food and Drug Administration form 2017 to 2019. Prior to joining the US FDA as commissioner, Gottlieb was a clinical assistant professor at the New York University School of Medicine.
Roland Diggelmann has been appointed to Accelerate Diagnostics' board of directors. Diggelmann is currently CEO of Smith+Nephew, a British medical equipment manufacturing company, having recently succeeded Namal Nawana, the former CEO of Alere. Diggelmann previously served as CEO of Roche Diagnostics, and also worked in the orthopedics sector at Sulzer Orthopedics and Zimmer Group.
Danaher has appointed Jessica Mega and Pardis Sabeti to its board of directors. Mega has been the chief medical and scientific officer at Verily Life Sciences since October 2015, and was previously a cardiologist and senior investigator at Brigham & Women's. She has also been a faculty member at Harvard Medical School and a senior investigator with the TIMI Study Group. Mega holds degrees from Stanford University, Yale University School of Medicine, and Harvard School of Public Health.
Jay Flatley has become chairman of the board of directors at Illumina. Until the end of 2019, he was executive chairman, and from 1999 until mid-2016, he was Illumina's CEO. Previously, he was president and CEO of Molecular Dynamics, now part of GE Healthcare. Before that, he was VP of engineering and strategic planning at Plexus Computers, executive VP at Manning Technologies, and held various positions at Spectra Physics.
Sophia Genetics has named former Foundation Medicine CEO Troy Cox chairman of its board of directors, effective March 1. Cox will replace Antoine Duchateau, whom the company said will remain on the board. Cox, who also has held executive positions at US BioOncology and Genentech, joined the Sophia Genetics board in July 2019.
Danaher this week announced a regular quarterly cash dividend of $.18 per share of its common stock, payable on April 24 to shareholders of record on March 27. The company’s board of directors also approved a quarterly cash dividend of $11.785 per share of its 4.75 percent Series A Mandatory Convertible Preferred Stock, payable on April 15 to shareholders of record on March 31.